SCHEMBL13289431

SCHEMBL13289431

Bc1cnn2c(NCc3cccc(CNS(=O)(=O)c4cccc(C)c4)c3)cc(-c3ccccc3Cl)nc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDK2 P24941 7/20 0.49
▸ GSK3B P49841 5/20 0.49
▸ KCNN3 Q9UGI6 1/20 0.41
▸ CYP1A2 P05177 4/20 0.41
▸ CYP2D6 P10635 4/20 0.41
▸ CYP2C19 P33261 4/20 0.41
▸ CYP3A4 P08684 3/20 0.41
▸ TSHR P16473 2/20 0.41
▸ CLK4 Q9HAZ1 1/20 0.41
▸ CYP2C9 P11712 1/20 0.38
▸ CCNA2 P20248 1/20 0.38
▸ CCNA1 P78396 1/20 0.38
▸ FBP1 P09467 1/20 0.38
▸ MEN1 O00255 1/20 0.37
▸ NPC1 O15118 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ CYP19A1 P11511 1/20 0.37
▸ TP53 P04637 1/20 0.37
▸ POLB P06746 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12954278 0.93 CDK2 (0.52) CDK2GSK3BCYP1A2CYP2D6CYP2C19
SCHEMBL13120624 0.91 CDK2 (0.62) CDK2GSK3BCCNA2CCNA1
SCHEMBL13288977 0.90 CDK2 (0.47) CDK2GSK3BMEN1KMT2ACYP19A1
SCHEMBL13289432 0.88 CDK2 (0.47) CDK2GSK3BCYP1A2CYP2D6CYP2C19
SCHEMBL13288973 0.88 CDK2 (0.48) CDK2GSK3BCYP1A2CYP2D6CYP2C19
SCHEMBL13289430 0.88 GSK3B (0.49) CDK2GSK3BKCNN3CYP1A2CYP2D6
SCHEMBL13289052 0.88 CDK2 (0.53) CDK2GSK3BCYP1A2CYP2D6CYP2C19
SCHEMBL13288958 0.88 GSK3B (0.46) CDK2GSK3BMEN1RAB9AKMT2A
SCHEMBL13288974 0.88 CDK2 (0.52) CDK2GSK3BCCNA2CCNA1MEN1
SCHEMBL13289375 0.88 CDK2 (0.54) CDK2GSK3BKCNN3CCNA2CCNA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2194058-A1 Pyrazolopyrimidines suitable for the treatment of cancer diseases SCHERING CORPORATION (US) 2010-06-09 — — EP disclosed
Send feedback